- Home
- NAKA vs AVTX Comparison
NAKA vs AVTX Comparison
Compare NAKA & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAKA | AVTX |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.2M | 248.3M |
| IPO Year | 2024 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NAKA | AVTX |
|---|---|---|
| Price | $0.38 | $15.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $4.50 | ★ $32.29 |
| AVG Volume (30 Days) | ★ 7.0M | 261.7K |
| Earning Date | 11-19-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,980,278.00 | $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,517.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.34 | $3.39 |
| 52 Week High | $34.77 | $20.72 |
Technical Indicators
Market Signals| Indicator | NAKA | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.19 | 42.98 |
| Support Level | $0.39 | $15.37 |
| Resistance Level | $0.44 | $17.12 |
| Average True Range (ATR) | 0.04 | 1.13 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 2.96 | 37.22 |
Price Performance
Historical ComparisonAbout NAKA Kindly MD Inc.
Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).